The Federal Food and Drug Administration (FDA) announced Thursday the approval of the oral antiviral drug Paxlovid. These are tablets for the treatment of mild to moderate cases of Covid-19 in adults.
According to the FDA, the pills are intended for people at high risk of progression to severe cases of coronavirus, including hospitalization or death.
Paxlovid is the fourth drug and the first oral antiviral pill approved by the FDA for the treatment of COVID-19 in adults.
“Although the pandemic has been a challenge for all of us, we have made great strides in mitigating the impact of Covid-19 on our lives. (…) Paxlovid has met the agency’s rigorous safety and efficacy standards and remains an important treatment option for those at high risk of progression to severe Covid-19. 19, including those who acquired pre-existing immunity,” said Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research.
At the same time, the agency stressed that Paxlovid produced under the emergency use authorization will continue to be available. It is intended for adults as well as the treatment of eligible children aged 12-18 who are not covered by Thursday’s approval decision.
-The FDA also noted that Paxlovid is not approved or approved “for use as pre- or post-exposure prophylaxis” to prevent COVID-19.
Andrzej Dobrowolski from New York
